Data as of October 23, 2026; trial data updated November 13, 2026
Research on CBD for inflammation in people is limited. CBD (cannabidiol), a non-intoxicating cannabinoid from hemp, lowered inflammation signals in lab and animal studies. In people, 5 of the 25 trials we reviewed that measured inflammation found lower markers or scores, including a placebo-controlled trial of 90 adults with gum disease in which a CBD gel improved gum-inflammation scores (Jirasek 2024); 4 had borderline or mixed results, 15 found no difference and 1 small pilot reported higher IL-6 with CBD, without a statistical test. The randomized CBD trials pooled in a 2026 meta-analysis showed no drop in blood markers.
The FDA has not approved CBD for inflammation. The FDA has approved only one drug that contains CBD: Epidiolex, a prescription medicine for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in people 1 year of age and older.
Jump to: Research | By the numbers | Mechanism | Conditions | Doses | Forms | Comparisons | Safety | Quality | Legal | FAQ | Every trial
What human studies show: 25 trials that measured inflammation (November 2026)
Does CBD reduce inflammation in people? Some trials found lower inflammation markers or scores, but most found no difference, and two recent meta-analyses found no meaningful drop in blood inflammation markers such as IL-6 (interleukin-6) and TNF-alpha (tumor necrosis factor alpha), cytokines, immune-cell signals that raise inflammation (2026, 2025). CRP (C-reactive protein) is a general sign of inflammation.
Of the 44 randomized trials in our review, 25 reported an inflammation marker or score. 14 measured none, 3 measured muscle or gut markers, and 2 have no verifiable inflammation result. All 53 human studies are in the appendix.
Of 13 placebo-controlled trials of CBD (without THC) that measured blood inflammation markers, 1 found lower IL-6, 2 had borderline or uncertain results, 9 found no difference and 1 reported higher IL-6. That trial was a pilot in 36 people having both knees replaced: blood IL-6 was higher in the groups given CBD (400 or 800 mg per dose, four doses around surgery) than with placebo (Sideris 2026). The abstract gives no p-value for IL-6, which was a secondary measure with 12 people per group. The trial’s registry results show IL-6 rose from before surgery to the next day by an average of 12.3 pg/mL on placebo, 20.6 at 400 mg and 17.7 at 800 mg, with no statistical test posted.
How the evidence has changed: before 2022, 3 of 5 trials that measured inflammation found lower markers or scores: a placebo-controlled THC and CBD spray in 58 people with rheumatoid arthritis (Blake 2006), a 10-person trial with no placebo (Hobbs 2020) and an exploratory analysis after 92 days of CBD in 48 people (Morissette 2021). Since 2022, 2 of 20 found lower markers or scores, led by a CBD gum-gel trial in 90 adults (Jirasek 2024); 4 were borderline or mixed, among them a CBD mouth paste that shrank canker sores more than placebo in 69 people (Umpreecha 2023); 13 found no difference and 1 reported higher IL-6 with no statistical test (Sideris 2026). Most of the newer placebo-controlled trials of CBD without THC (Crippa 2022 to Sideris 2026) enrolled healthy adults, athletes or exercise volunteers. Small trials on both sides, such as Stone 2023 (4 people) and Hobbs 2020 (10), can miss a real effect or overstate one.
| Study | People (n) | CBD a day, length | Result |
|---|---|---|---|
| Morissette 2021 | Cocaine use disorder, 48 | 800 mg, 92 days | IL-6 lower (exploratory) |
| Johnson 2025 | Exercise in heat, 13 | 298 mg once | IL-6 borderline lower |
| Sahinovic 2022 | Endurance-trained men, 9 | 300 mg once | IL-1beta possibly lower; IL-6, TNF-alpha: unclear (pilot) |
| Crippa 2022 | COVID-19, 91 | 300 mg, 14 days | IL-6, TNF-alpha: no difference (CRP fell in both groups) |
| Gurgenci 2023 | Advanced cancer, about 140 | 50-600 mg, 28 days | CRP: no difference |
| Townsend 2024 | Healthy adults, 102 | 30-60 mg drink*, 8 weeks | CRP: no difference |
| Mastrofini 2024 | Healthy adults, 54 | 100 mg, about 12 weeks | No difference |
| Flores 2023 | Healthy adults, 48 | 50 mg, 8 weeks | CRP: no difference |
| Crossland 2022 | Female athletes, 24 | 5 mg/kg x3, 12 hours | No difference |
| Isenmann 2024 | Athletes, 17 | 60 mg per session, 6 days | IL-6: no difference |
| Ewell 2026 | Overweight adults, 16 | 60 mg, 4 weeks | No difference |
| Stone 2023 | Exercise, 4 | 2 or 10 mg/kg twice daily, 2 days | IL-6: no difference |
| Sideris 2026 | Knee-replacement surgery, 36 | 400 or 800 mg per dose, 4 doses around surgery | IL-6 higher in the CBD groups (pilot; no p-value in the abstract) |
| Study | People (n) | Result |
|---|---|---|
| Jirasek 2024 | Gum disease, 90 | Gum-inflammation scores improved |
| Umpreecha 2023 | Mouth ulcers (canker sores), 69 | Ulcers smaller than placebo at every check; redness smaller on day 2 only |
| Botanix 2022 (registry) | Acne, 368 | Inflamed lesions: no difference |
| Hobbs 2020 (no placebo) | Healthy adults, 10 | Lab-tested TNF lower |
| Kuntzman 2025 | COVID-19, 10 | Cytokines mixed |
| Naftali 2021 (with THC) | Crohn’s disease, 56 | CRP: no difference |
| Irving 2018 (with THC) | Ulcerative colitis, 60 | CRP: no difference |
| Mitarnun 2025 (with THC) | Parkinson’s, 51 | No difference |
| Blake 2006 (THC:CBD spray) | Rheumatoid arthritis, 58 | DAS28 score 0.76 lower |
| Mboumba Bouassa 2023 (no placebo) | HIV, 10 | Some markers lower |
| Colorado 2024 (with THC, registry) | Parkinson’s, 36 | IL-6 not lower (no test posted) |
| Montefiore 2025 (with THC, registry, observational) | HIV, 26 | Cytokines: no change |
*Drink with L-theanine and vitamins. Registry: results posted on ClinicalTrials.gov, not peer reviewed. DAS28: a rheumatoid arthritis activity score.
For the doses used in these studies and what they mean, see How much CBD should I take for inflammation? below.
CBD for Inflammation by the numbers (October 2026)
| Metric | Value |
|---|---|
| Registered CBD studies tied to inflammation | 79, plus 22 testing CBD with THC |
| Studies that make inflammation the main outcome | 17 of 79 |
| Completed CBD studies with posted results | 11 of 35 (31.4%) |
| PubMed papers on cannabidiol and inflammation | 1,749 (29 in 2015, 245 in 2025); 35 (2.0%) tagged as randomized trials |
| US monthly searches for “cbd for inflammation” | Peak 3,046 (July 2019); 875 a month, October 2025 to September 2026 (71.3% below peak); 1,005 in September 2026 |
The number of registered studies shows research interest, not whether CBD works.
Cite this data: Cannabidiol Life, “CBD for Inflammation by the numbers (October 2026),” cbdoilsandedibles.com, https://cbdoilsandedibles.com/health/cbd-for-inflammation/, data as of 2026-10-23.
How might CBD affect inflammation? What lab and animal studies show
In lab and animal studies, CBD lowered inflammatory cytokines (Henshaw 2021) and acted as an antioxidant (Hampson 1998) through several targets, including endocannabinoid system receptors. In cell and animal studies gathered in a 2019 review, CBD also switched on Nrf2, a protein that turns on the cell’s own antioxidant genes. It also boosted the antioxidant enzyme superoxide dismutase in a mouse model of diabetic heart disease and in human heart cells. The review notes the effects depend on concentration (Atalay 2019). A 2020 review of cell and animal studies reported that CBD suppressed the activation of several types of immune cell, triggered the death (apoptosis) of immune cells and promoted regulatory cells that hold other immune cells in check. No single CBD receptor has been definitively identified for these effects, and a few reports found immune-enhancing effects (Nichols 2020). These routes have not yet been confirmed in people; for results in people, see the trials above.
| Target | Lab or animal finding |
|---|---|
| CB1, CB2, TRPV1 | Binds CB1 and CB2 weakly, mostly blunting them (Thomas 2007). In lab tests it inhibited the triggered movement (migration) of immune cells: mouse microglial cells and macrophages, and human neutrophils. A review says its action on CB2 may explain this, with more research needed (Pertwee 2008). Switches TRPV1 on, then desensitizes it (Bisogno 2001) |
| Adenosine A2A receptor | In mice, CBD’s effect on inflammation depended on it (Carrier 2006) |
| PPAR-gamma | In rats, blocking it blunted CBD’s effects (Esposito 2011). A 2016 review of lab and animal studies adds that CBD bound to it and raised its activity in lab tests. In mice given LPS (a bacterial toxin), the review says, CBD’s anti-inflammatory effects in the gut worked through it. PPAR receptors accounted for some, but not all, of the anti-inflammatory effects of some cannabinoids (O’Sullivan 2016) |
In a lab study of joint-lining cells (synovial fibroblasts) from rheumatoid arthritis, CBD lowered IL-6 (Lowin 2020). It did so at about 2 to 4 times the highest average peak blood level in a high-dose human trial (Taylor 2018), well above the levels after a low dose (Hobbs 2020).
Inflammatory conditions studied: arthritis, gut, skin, heart and more
| Area | What studies we reviewed found (as of November 13, 2026; limited evidence) |
|---|---|
| Joints | Rheumatoid arthritis: the DAS28 activity score was 0.76 lower with a THC and CBD spray in a placebo-controlled trial of 58 people (Blake 2006). Joint symptoms from breast cancer hormone therapy: in an open-label study of 39 women with no control group, nine blood cytokines were lower after 15 weeks of CBD, up to 100 mg twice a day (an exploratory result, with cytokine data for 20 women); cytokines in lab-stimulated blood did not change (Fleege 2025). CBD-only knee and hand arthritis trials (86, 45 and 136 people): pain, no difference. See CBD for arthritis. |
| Muscles, tendons, swelling | A 2026 placebo-controlled trial in 29 healthy adults reported less pain after an exercise-induced muscle injury (Stauffer 2026), and a drink combining CBD with CBG and other ingredients had a modest effect on soreness (Peters 2023); most other exercise trials, including one on arm swelling, found no difference. No tendon trial. After knee-replacement surgery, a placebo-controlled pilot trial in 36 people found higher blood IL-6 in the CBD groups (the abstract gives no p-value); opioid use, its main goal, did not differ significantly, though a post hoc test favored the 400 mg dose (Sideris 2026); no trial measured swelling after surgery. See CBD for pain. |
| Skin, scalp | Psoriasis: in a 2026 placebo-controlled trial of 28 people taking CBD oil by mouth, itch scores fell by week 8, though the skin score showed no significant improvement (Roongpisuthipong 2026). Acne: small, mostly non-randomized studies reported fewer lesions and less redness (Komane 2026 review). The large acne and eczema trials: no difference. No scalp trial. |
| Gut (bowel, intestines), stomach | Pooled 2025 analysis of 8 trials of cannabis products, most with THC: quality of life improved in both Crohn’s disease and ulcerative colitis, and Crohn’s activity scores fell; inflammation markers and endoscopy scores did not (Kang 2025). The one CBD-only Crohn’s trial: no difference (Naftali 2017). Animal research on cannabinoids as a group: a 2026 pooled analysis covered 27 studies (408 animals) using models of inflammatory bowel disease. Treated animals had lower disease activity and tissue-damage scores, and lower myeloperoxidase, TNF-alpha, IL-6 and IL-1beta, than untreated ones (Wang 2026). Its authors rate the certainty as limited because randomization was unclear, studies were not blinded, results varied widely and samples were small. No trial of stomach inflammation (gastritis). |
| Gums and mouth | 2024 placebo-controlled trial, 90 adults with gum disease: a CBD gel improved gum-inflammation scores (Jirasek 2024). Canker sores: in a placebo-controlled trial of 69 people, a 0.1% CBD mouth paste shrank ulcers more than placebo at every check over 7 days; the red, inflamed border was smaller on day 2 only, and CBD shrank ulcers and redness less than a steroid paste, though the difference was not significant (Umpreecha 2023). A 2025 review found 7 clinical studies of CBD for mouth conditions, 6 of them randomized: they reported less pain, gum inflammation and mouth-ulcer symptoms but differed too much to be pooled (de Abreu 2025). |
| Heart | Myocarditis: in a placebo-controlled trial of 109 people, the main heart-MRI goals were not met (McNamara 2026). Pericarditis: CRP was normal again in 8 of 10 people with high CRP in an open-label trial with no control group (Luis 2026). |
| Lungs, liver | In mice with acute lung injury, CBD lowered lung inflammation; no trial we reviewed measured lung or liver inflammation in people. COVID-19 trial: IL-6 and TNF-alpha no different from placebo (Crippa 2022). Lung data: mice (Ribeiro 2012). |
| Brain | Alzheimer’s-type inflammation: CBD reduced it in rats (Esposito 2011); no human trial. Parkinson’s trials, both with THC: markers not lower. |
| Prostate | In a 2026 open-label pilot of 16 men with chronic prostatitis using a CBD-hyaluronic acid suppository, the symptom score fell from 24.5 to 20.0; the study had no placebo group and measured no inflammation marker (Student 2026). |
| Whole body (chronic, systemic), autoimmune | Healthy adults: lab-tested TNF was lower in a 10-person trial with no placebo (Hobbs 2020), and in a 23-person study with no control group, TNF-alpha was lower but IL-6 higher in lab-stimulated cells (Gisch 2026). Placebo-controlled trials in healthy and overweight adults: markers unchanged in most; two small exercise trials had borderline or uncertain drops (Johnson 2025, Sahinovic 2022). Autoimmune: see joints, gut and skin. |
| Sinuses and nose, bladder, eyes | No human trial we reviewed measured inflammation here. |
As of November 13, 2026, the six further reviews below (one of them a meta-analysis) each reported a benefit or a favorable signal in people; they are a selection, not a full list. Reviews that found no significant effect on inflammation are cited above. Two meta-analyses found no meaningful drop in blood inflammation markers (see What human studies show). Kang 2025, in the Gut row, found that inflammation markers and endoscopy scores did not fall. The five gut reviews below, like Kang 2025, draw on the same few small trials, most of them of products that contain THC, so they are not independent results.
| Review | What it covered | What it reported | Its own limit |
|---|---|---|---|
| Zintziovas 2026 | Rheumatoid arthritis pain. A scoping review that found 3 eligible studies among 593 records. One was a randomized, placebo-controlled trial of a THC and CBD mouth spray (58 patients). The other 2 were observational: a survey of people with arthritis who had used CBD and a hospital-records study of cannabis use. | In its one randomized trial, the spray reduced pain on movement by 0.95 points and pain at rest by 1.04 points, and the DAS28 activity score fell by 0.76 points. This is the Blake 2006 spray trial already in the Joints row above, not a second result. The two observational studies suggested possible symptom benefit. | The authors conclude the evidence remains insufficient to establish that cannabinoids help rheumatoid arthritis pain. Only 3 studies; the observational ones were at serious to critical risk of bias. |
| Jugl 2026 | Crohn’s disease and ulcerative colitis in adults. A systematic review of 4 randomized trials and 4 observational studies of cannabis products that contain THC. It excluded CBD-only and hemp products (no THC or less than 0.3% THC), FDA-approved cannabinoid drugs and products used on the skin. | In one trial of 56 people (Naftali 2021, in the trial tables above), bloating and appetite improved with an oil of 16% CBD and 4% THC taken by mouth; both results were rated low evidence quality. Disease activity scores were mixed across 4 trials (180 people). | Remission (3 trials, 150 people) and endoscopic scores (2 trials, 88 people) were no different from control. All 4 trials were at high risk of bias, and the authors call the evidence inconclusive. |
| Doeve 2021 | Inflammatory bowel disease. A meta-analysis of 5 randomized trials and 15 nonrandomized studies of cannabis or cannabinoids of any kind, not CBD alone. Its remission analysis included 146 randomized participants. | Patient-reported symptoms (abdominal pain, general well-being, nausea, diarrhea and poor appetite) and quality-of-life scores improved with cannabis or cannabinoids. | Remission was not significantly more likely (risk ratio 1.56; 95% confidence interval 0.99 to 2.46), and inflammatory biomarkers did not change. Risk of bias was moderate. |
| Swaminath 2019 | Inflammatory bowel disease. A white paper commissioned by the Crohn’s and Colitis Foundation: a narrative (not systematic) review of lab, animal, human, safety and regulatory information on medical cannabis, not CBD alone. It gives no pooled numbers. | Human studies found benefit in controlling symptoms and improving quality of life, and animal models gave evidence of anti-inflammatory, antidiarrheal and pain-limiting properties. | No study established true disease modification (a change in the disease itself): biomarker profiles and endoscopic healing did not improve. |
| Kafil 2018 (Crohn’s) | Active Crohn’s disease in adults. A Cochrane review of 3 small randomized trials (93 participants), not pooled because the products differed. They tested cannabis cigarettes with 115 mg of THC, cannabis oil with 15% CBD and 4% THC, and cannabis oil with 5% CBD (Naftali 2017, in the Gut row above; the review counts 22 people, the trial itself 20). | Oil with 15% CBD and 4% THC (50 people): after 8 weeks the mean Crohn’s activity score (CDAI) was lower, 118.6 vs 212.6 on placebo, and the quality-of-life score higher, 96.3 vs 79.9; both low-certainty evidence. THC cigarettes (21 people): 91% (10 of 11) had a clinical response vs 40% (4 of 10) on placebo; very low certainty. | With the THC cigarettes, the effect on remission was unclear (45% vs 10% on placebo; very low certainty). The 5% CBD oil showed no difference in remission (40% vs 33% on placebo; very low certainty). The review calls the effects of cannabis and cannabis oil on Crohn’s disease uncertain. |
| Kafil 2018 (colitis) | Ulcerative colitis in adults. A Cochrane review of 2 randomized trials (92 participants), not pooled because the products differed. One tested cannabis cigarettes giving 23 mg of THC a day for 8 weeks (32 people). The other tested CBD capsules with up to 4.7% THC, 100 to 500 mg of CBD a day for 10 weeks (60 people; Irving 2018, in the trial tables above). | THC cigarettes: after 8 weeks the mean disease activity index was lower, 4 vs 8 on placebo, an effect the review calls uncertain. CBD capsules with up to 4.7% THC: the review says there may be a clinically meaningful improvement in quality of life at 10 weeks (mean difference 17.4 on the IBDQ scale). Its 95% confidence interval, -3.45 to 38.25, includes no difference; the review rates the evidence moderate certainty. | With the capsules, remission (24% vs 26% on placebo) and CRP (9.428 vs 7.638 mg/L) were similar to placebo, and adverse events, which the review calls mild or moderate, were more frequent. The review calls the effects of cannabis and cannabidiol on ulcerative colitis uncertain. |
How much CBD should I take for inflammation? Doses used in studies
There is no official dose of CBD for inflammation, and research does not show what amount works for a given person. In CBD-only trials, adults received fixed doses of 20 to 800 mg a day (Naftali 2017, Morissette 2021); the trial that found lower IL-6 used 800 mg a day for 92 days, and one surgery trial gave four doses of 400 or 800 mg each (Sideris 2026). A 2019 review of CBD dosing found no sign of benefit in small trials in Crohn’s disease, diabetes, fatty liver disease and chronic pain. Those trials used low doses, 2.4 mg per kg a day on average, against 15 mg per kg a day in epilepsy trials (Millar 2019). Some heart-inflammation trials dosed by body weight, up to 10 mg per kg twice a day (McNamara 2026, Luis 2026). These are the amounts researchers used in studies. They are not dosing advice.
Label math: if a 30 mL bottle’s label says it holds 1,500 mg of CBD, each mL holds 50 mg. For joint conditions, see CBD for arthritis.
What forms of CBD have inflammation studies used?
No study we reviewed tested CBD gummies, patches or vapes for inflammation. Most trials of CBD oil for inflammation gave oil or capsules by mouth, which peaked in the blood about 4 hours after a dose in a study of 8 men (Johnson 2024).
| Form | In inflammation trials? | What to know |
|---|---|---|
| Oil or tincture, capsule | Most marker trials | About 6% absorbed fasting (Perucca 2020) |
| Gummy, drink | One drink trial | 70% of 56 gummy products missed their labeled amount by more than 10% (Johnson ED 2025) |
| Cream, gel, balm, roll-on | Gels, liquids and a mouth paste | No balm, salve, lotion or roll-on trial measured inflammation |
| Spray, patch, vape, smoked flower | Nabiximols spray; smoked flower | Vaping typically not recommended (Arthritis Foundation) |
Does CBD cream help with inflammation?
For gum inflammation, a CBD gel improved gum-inflammation scores in a 2024 placebo-controlled trial of 90 adults with gum disease (Jirasek 2024). A 0.1% CBD mouth paste shrank canker sores more than placebo in a trial of 69 people, with redness smaller on day 2 only (Umpreecha 2023). For skin, small early studies, mostly without a randomized comparison group, reported fewer acne lesions and less redness with CBD products, often mixed with other active ingredients (Komane 2026 review); the two large controlled trials, in acne and eczema, found no difference from the vehicle. Menthol, capsaicin or camphor in many topicals make effects hard to credit to CBD (Arthritis Foundation).
CBD vs THC, CBG and ibuprofen: what studies compared
On CBD vs THC for inflammation, in a 2026 study of 108 adults smoking flower, higher blood THC went with larger marker rises (Bryan 2026). In two 4-week studies of legal-market cannabis flower, each compared with non-users rather than placebo, blood markers did not change whether the flower was CBD-dominant, THC-dominant or mixed (Bryan 2025; Lisano 2025, 171 adults with anxiety); in the first, regular users had lower markers than non-users. The one rheumatoid arthritis trial, of nabiximols (Sativex), a THC and CBD mouth spray the FDA has not approved, found a lower arthritis activity score (Blake 2006; FDA).
One small study tested CBG alone, not CBD: in 20 healthy volunteers with detergent-irritated skin, a 0.1% CBG serum reduced redness more than a placebo serum over 2 weeks (Perez 2022). No trial we reviewed compared CBD with CBN, turmeric, prednisone or full-spectrum products; one mouth-ulcer trial compared a CBD paste with a steroid paste: CBD shrank ulcers and redness less, though the difference was not significant (Umpreecha 2023). Hemp seed oil is not CBD oil: the FDA says hemp seeds do not naturally contain CBD or THC (FDA).
Has CBD been compared with ibuprofen for inflammation?
No trial in our review compared CBD with ibuprofen for inflammation. The one trial we found with an ibuprofen-and-acetaminophen group (Abidi 2025) measured pain after tooth extraction in 8 people, 2 per group. Advil is a brand of ibuprofen, so the same answer applies.
Do not stop, reduce or change any prescribed medicine or treatment without talking to the doctor who prescribed it.
Is there a downside to taking CBD?
Side effects can happen: in trials, CBD caused more diarrhea, sleepiness and loss of appetite than placebo; outside childhood-epilepsy trials, diarrhea was the one that stood out (Chesney 2020). Talk to your doctor or pharmacist before using CBD, especially if you take any medicines or supplements, have liver problems, or have a health condition.
The CDC lists liver damage and mood changes (CDC); the FDA cites possible male reproductive harm (FDA 2023). In an FDA-run trial in healthy adults taking 5 mg/kg of CBD a day for 4 weeks, 5.6% of those on CBD had liver-enzyme rises above 3 times normal, vs none on placebo (Florian 2025).
Drug interactions
CBD can affect how other medicines work, which can cause serious side effects. Using CBD with alcohol or with medicines that cause drowsiness, such as some medicines for anxiety, panic, stress or sleep, raises the risk of sleepiness and injury.
The liver enzymes CYP3A4 and CYP2C19 break CBD down. In people taking prescription CBD (Epidiolex) at seizure-treatment doses with the seizure medicines valproate and clobazam, liver enzymes rose more often (Epidiolex label). Case reports suggest CBD can raise warfarin’s blood-thinning effect (Smythe 2023). CBD raised peak levels of the immune-suppressing drug tacrolimus about fourfold (So 2025).
Can I take CBD with ibuprofen?
The concern is mostly theoretical. The Arthritis Foundation lists ibuprofen (Advil), naproxen, acetaminophen, prednisone and some antidepressants among drugs that could possibly interact with CBD, mostly in theory or from animal studies. A 2021 review adds alcohol and cites no human study of CBD taken with ibuprofen or another NSAID (Balachandran 2021).
Who should avoid CBD
Do not use CBD if you are pregnant, planning a pregnancy or breastfeeding. The FDA strongly advises against using CBD, THC or marijuana in any form during pregnancy or while breastfeeding.
CBD products are not for children. Keep them out of reach of children and pets. If a child swallows a CBD or THC product, call Poison Control at 1-800-222-1222 or get medical care right away.
People with reduced liver function had 2.6 to 5.2 times higher CBD blood levels (Jang 2024).
When to see a doctor
Get emergency care (call 911) for sudden, severe or unexplained pain, chest pain, trouble breathing, or signs of a stroke.
The Arthritis Foundation says CBD does not take the place of disease-modifying treatment for inflammatory arthritis such as rheumatoid arthritis (Arthritis Foundation).
How to check a CBD product’s quality
How to check a CBD product’s quality: read its certificate of analysis (COA) from an accredited third-party lab. See our guides to reading a COA and verifying the lab.
- A batch-matched COA from an independent lab using methods approved by AHP, USP, NSF International or AOAC, and a maker that follows good manufacturing practices (GMP), voluntary for CBD (Arthritis Foundation).
- Tests for heavy metals, pesticides and microbes, which the CDC says can turn up (CDC), and for residual solvents.
- The THC amount. Some CBD products contain THC, even when the label says they don’t. Using CBD can lead to a positive drug test: in a 2026 controlled study, at least one person in every group taking CBD oil with a little THC tested positive, as did one urine sample from the CBD-only group (Wolinsky 2026). 39% of 56 CBD gummy products tested in 2025 contained THC (Johnson ED 2025).
- CBD per serving that matches the label.
In a 2024 test of 202 US products, 74% missed their labeled CBD amount by 10% or more. Heavy metals turned up in 44 products, residual solvents in 181 and pesticides in 30; only 1% to 3% of detections exceeded a regulatory limit (Gidal 2024).
Is CBD legal?
Is CBD legal? Federal law is changing. Under the 2018 Farm Bill definition, hemp (including hemp-derived CBD) is cannabis with no more than 0.3% delta-9 THC by dry weight, and it is not a controlled substance. A new federal definition applies in two steps (section 781 of Public Law 119-37, with start dates set by Public Law 119-103). Starting November 12, 2026, hemp products that contain cannabinoids the plant cannot produce naturally no longer count as hemp. Starting December 11, 2026, the rest of the definition applies. It counts total THC, including THCA, and a finished hemp product such as a CBD oil or gummy qualifies as hemp only if each container holds no more than 0.4 mg of total THC and similar cannabinoids, and contains no cannabinoids that were synthesized or manufactured outside the plant. Some full-spectrum CBD products contain more THC than that. State laws differ and can be stricter. This is general information, not legal advice.
The FDA explains how it regulates CBD products on its question-and-answer page (FDA).
Frequently asked questions about CBD for inflammation
Does CBD actually lower inflammation?
Some trials found lower inflammation, but most found no difference. In a placebo-controlled trial of 90 adults with gum disease, a CBD gel improved gum-inflammation scores (Jirasek 2024). For blood markers, CBD trials pooled in a 2026 meta-analysis showed no drop, and 9 of 13 placebo-controlled trials we reviewed found no difference; one found lower IL-6 in 48 adults (Morissette 2021), two had borderline or uncertain results and one reported higher IL-6 with no statistical test (Sideris 2026).
How long does it take CBD to affect inflammation?
No trial we reviewed measured how fast CBD affects inflammation. In a study of 8 men, oil held under the tongue and capsules both peaked in the blood about 4 hours after a dose (Johnson 2024), not 15 to 45 minutes. The trial that found lower IL-6 gave CBD daily for 92 days (Morissette 2021).
Can CBD cause inflammation?
Most trials we reviewed that measured inflammation found no difference either way, and trials pooled in a 2026 meta-analysis showed a small, uncertain rise in blood markers. One placebo-controlled pilot trial, in 36 people having knee-replacement surgery, found higher blood IL-6 in the CBD groups; its abstract gives no p-value (Sideris 2026). In a 2026 before-and-after study of 23 healthy adults with no control group, CBD lowered TNF-alpha but raised IL-6 in lab-stimulated cells; its authors described the effects as mixed, both anti-inflammatory and pro-inflammatory (Gisch 2026).
What should you look for in a CBD product for inflammation?
No inflammation trial compared product types, so check quality: a batch-matched COA from an accredited lab, the THC amount and CBD per serving. In a 2024 test, 74% of 202 US products missed their labeled CBD amount by 10% or more (Gidal 2024).
Does CBD help with inflammation and pain?
Some placebo-controlled trials found less short-term pain: toothache in 61 people (Chrepa 2024) and exercise-induced muscle injury in 29 (Stauffer 2026). For chronic pain, a 2025 federal (AHRQ) review found CBD alone no better than placebo in 4 randomized trials, and CBD-only knee and hand arthritis trials (86, 45 and 136 people) found no pain difference. See CBD for pain and CBD for arthritis.
How we researched this
We do not sell or recommend products on this page. Every study cited was checked at PubMed or the publisher. Figures from Cannabidiol Life’s Evidence Tracker show the date and source used. On October 23, 2026 we searched PubMed and ClinicalTrials.gov for human CBD studies of inflammation and list every study we kept, including no-difference findings. On November 13, 2026 we searched Cannabidiol Life’s research library of 5,059 PubMed records and found 1,024 papers on CBD or medical cannabis and inflammation that were not yet in our review. We checked 73 of them at PubMed and added 12 papers that met this page’s rules, including 7 human studies now in the appendix. That day we also added 11 more sources from our October research: 6 reviews of human studies and 5 reviews of lab and animal research. Each reported a favorable result, and they are a selection, not a full list of reviews.
More: CBD and health guides.
Every human trial in our review
| Study | Design | People (n) | Result |
|---|---|---|---|
| Measured an inflammation marker or score (25) | |||
| Morissette 2021 | Randomized, placebo (exploratory) | Cocaine use disorder, 48 | IL-6 lower |
| Johnson 2025 | Randomized crossover, placebo | Exercise in heat, 13 | IL-6 borderline lower |
| Sahinovic 2022 | Randomized crossover, placebo (pilot) | Endurance-trained men, 9 | IL-1beta possibly lower; IL-6, TNF-alpha: unclear (authors: changes too small to judge reliably) |
| Crippa 2022 | Randomized, placebo | COVID-19, 91 | IL-6, TNF-alpha: no difference (CRP fell in both groups) |
| Gurgenci 2023 and Hardy 2023 (same trial) | Randomized, placebo | Advanced cancer, 144 (CRP in about 140) | CRP: no difference; symptoms: no difference |
| Townsend 2024 | Randomized, placebo | Healthy adults, 102 | CRP: no difference |
| Mastrofini 2024 | Randomized, placebo | Healthy adults, 54 | No difference |
| Flores 2023 | Randomized, placebo | Healthy adults, 48 | CRP: no difference |
| Crossland 2022 | Randomized crossover, placebo | Female athletes, 24 | No difference |
| Isenmann 2024 | Randomized crossover, placebo | Athletes, 17 | IL-6: no difference |
| Ewell 2026 | Randomized, placebo | Overweight adults, 16 | No difference |
| Stone 2023 | Randomized crossover, placebo | Exercise, 4 | IL-6: no difference |
| Sideris 2026 | Randomized, placebo (pilot) | Knee-replacement surgery, 36 | IL-6 higher in the CBD groups (no p-value in the abstract); opioid use (main goal): no significant difference; a post hoc test favored 400 mg |
| Jirasek 2024 | Randomized, placebo | Gum disease, 90 | Gum-inflammation scores improved |
| Umpreecha 2023 | Randomized, placebo and steroid-paste groups | Mouth ulcers (canker sores), 69 | Ulcers smaller than placebo at every check; redness smaller on day 2 only; no significant difference from the steroid paste |
| Botanix 2022 (registry) | Randomized (registry results) | Acne, 368 | Inflamed lesions: no difference |
| Hobbs 2020 (no placebo) | Randomized, no placebo | Healthy adults, 10 | Lab-tested TNF lower |
| Kuntzman 2025 | Randomized, placebo | COVID-19, 10 | Cytokines mixed |
| Naftali 2021 (with THC) | Randomized, placebo | Crohn’s disease, 56 | CRP: no difference |
| Irving 2018 (with THC) | Randomized, placebo | Ulcerative colitis, 60 | CRP: no difference |
| Mitarnun 2025 (with THC) | Randomized, placebo | Parkinson’s, 51 | No difference |
| Blake 2006 (THC:CBD spray) | Randomized, placebo | Rheumatoid arthritis, 58 | DAS28 score 0.76 lower |
| Mboumba Bouassa 2023 (no placebo) and Mboumba Bouassa 2024 (same trial) | Randomized, no placebo | HIV, 10 | Some markers lower; 2 of 10 withdrawn for safety reasons |
| Colorado 2024 (with THC, registry) and Weber 2024 (same trial) | Randomized, placebo (registry results) | Parkinson’s, 74 (IL-6 in 36) | IL-6 not lower (no test posted); seborrheic dermatitis: no difference |
| Montefiore 2025 (with THC, registry, observational) | Randomized; registry lists it as observational (registry results) | HIV, 26 | Cytokines: no change |
| No inflammation result (19) | |||
| McNamara 2026 | Randomized, placebo | Myocarditis, 109 | Heart MRI: main goals not met |
| Roongpisuthipong 2026 | Randomized, placebo | Psoriasis, 28 | Skin score: no difference; itch lower |
| Stauffer 2026 | Randomized, placebo | Muscle injury, 29 | Pain lower (feasibility) |
| Pastina 2025 | Randomized, placebo | Exercise soreness, 28 | Soreness: no difference |
| Abidi 2025 | Randomized pilot, placebo and ibuprofen-and-acetaminophen groups | Tooth extraction, 8 | Pain, 2 per group (descriptive only) |
| Chrepa 2024 | Randomized, placebo | Toothache, 61 | Pain lower |
| Pramhas 2023 | Randomized, placebo | Knee arthritis, 86 | Pain: no difference |
| Mojoli 2025 | Randomized, placebo | Knee arthritis, 45 | Pain: no difference |
| Vela 2022 | Randomized, placebo | Hand or psoriatic arthritis, 136 | Pain: no difference |
| Cochrane-Snyman 2021 | Randomized crossover, placebo | Exercise, 13 | Soreness, arm swelling: no difference |
| Naftali 2017 | Randomized, placebo | Crohn’s disease, 20 | Crohn’s activity score: no difference |
| Peters 2023 (with CBG) | Randomized, placebo | Exercise soreness, 40 | Soreness: modest effect |
| Gao 2022 (combination) | Randomized, placebo | Eczema, 57 | CBD-only arm: no difference |
| Botanix 2022 (registry) | Randomized (registry results) | Eczema, 200 | Clear or almost-clear skin: 12% vs 19% on vehicle |
| Mendes 2026 | Randomized crossover, placebo | Muscle damage, 15 | Myoglobin, soreness: no difference |
| Isenmann 2021 | Randomized crossover, placebo | Strength training, 16 | Muscle-damage markers: small differences |
| Couch 2019 | Randomized, placebo | Healthy men, 30 | Gut permeability lower |
| Jadoon 2016 | Randomized, placebo | Type 2 diabetes, 62 | Inflammation markers measured; no CBD-vs-placebo result in abstract |
| Couton 2026 | Randomized, placebo | HIV, 80 | Inflammation results unpublished |
| Non-randomized studies (9) | |||
| Luis 2026 | Open-label, single arm, no control | Recurrent pericarditis, 27 | CRP normal in 8 of 10 with high CRP |
| Gisch 2026 | Before/after, no control | Healthy adults, 23 | In lab-stimulated cells (cytokines tested in 3): TNF-alpha lower, IL-6 higher |
| Fleege 2025 | Single arm, open-label (no control) | Joint symptoms from breast cancer hormone therapy, 39 | Nine blood cytokines lower at week 15 (exploratory; data for 20 women); lab-stimulated cytokines: no change; worst pain 2 or more points lower in 17 of 39, short of the trial’s main goal |
| Yeshurun 2015 | Historical controls | Stem-cell transplant, 48 | Acute graft-versus-host disease rate compared only with past patients; no randomized control group |
| Marini 2024 | Single arm | HIV, 3 | Gene-expression changes |
| Bryan 2026 | Quasi-randomized, smoked flower | Healthy adults (no cannabis in prior 3 months), 108 | Higher blood THC, larger rise in markers |
| Bryan 2025 | Quasi-randomized product (users could decline it), cannabis flower for 4 weeks, compared with non-users | Healthy adults who use cannabis, and non-users (number not stated in the abstract) | Markers lower in users than non-users; no change by CBD-to-THC ratio over 4 weeks |
| Lisano 2025 | Quasi-experimental, cannabis flower for 4 weeks, compared with non-users | Adults with anxiety, 171 (52 on CBD-dominant flower) | Cytokines: no change in any group |
| Student 2026 | Single arm, open-label (no placebo) | Chronic nonbacterial prostatitis, 16 | Symptom score 24.5 to 20.0; no inflammation marker. The product’s maker supported the study. |
Important safety and legal information
Sources
- Belvederi Murri M, Guglielmo R, Zizzi A, Muscettola A, Nanni MG, Dall’Oro M, et al. (2026). Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis. Brain Behav Immun, 135:106517.
- Candeloro BM, de Oliveira CM, Gimenez FVM, Barbosa MPCN, Soares BP, Ruiz ACF, et al. (2025). The Pleiotropic Influence of Cannabidiol and Tetrahydrocannabinol on Inflammatory Biomarkers: A Systematic Review and Meta-Analytical Synthesis. Int J Mol Sci, 26(23).
- Kang H, Schmoyer CJ, Weiss A, Lewis JD (2025). Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease. Inflamm Bowel Dis, 31(2):450-460.
- Chou R, Ahmed AY, Dana T, Morasco BJ, Bougatsos C, Fu R, Williams L (2025). Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update (Comparative Effectiveness Review No. 250; Report No. 25-EHC036). Agency for Healthcare Research and Quality (AHRQ), NBK618045.
- Henshaw FR, Dewsbury LS, Lim CK, Steiner GZ (2021). The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. Cannabis Cannabinoid Res, 6(3):177-195.
- Arthritis Foundation (2024). CBD for Arthritis Pain: What You Should Know. arthritis.org (Updated July 29, 2024).
- US Food and Drug Administration (2024). FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). FDA Q&A page (Content current as of 07/16/2024).
- US Food and Drug Administration (2023). FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward. FDA statement, January 26, 2023.
- Centers for Disease Control and Prevention (CDC) (2025). About CBD. CDC Cannabis and Public Health (page dated 2025-01-31).
- Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G (2020). Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis, 11(8):714.
- Carrier EJ, Auchampach JA, Hillard CJ (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A, 103(20):7895-900.
- Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Mariano-Souza DP, Quinteiro-Filho WM, et al. (2012). Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor. Eur J Pharmacol, 678(1-3):78-85.
- Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, et al. (2011). Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS One, 6(12):e28668.
- Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol, 150(5):613-23.
- Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol, 134(4):845-52.
- Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A, 95(14):8268-73.
- Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (2018). A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs, 32(11):1053-1067.
- Perucca E, Bialer M (2020). Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs, 34(8):795-800.
- Johnson DA, Funnell MP, Heaney LM, Cable TG, Wheeler PC, Bailey SJ, et al. (2024). Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males. Cannabis Cannabinoid Res, 9(5):e1423-e1432.
- Jang JH, Jeong JH, Jeong SH (2024). Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis. Naunyn Schmiedebergs Arch Pharmacol, 397(11):8285-8309.
- Jazz Pharmaceuticals (2026). EPIDIOLEX (cannabidiol) oral solution: Full Prescribing Information (revised 5/2026; Medication Guide revised 7/2025). DailyMed (NLM), set ID 8bf27097-4870-43fb-94f0-f3d0871d1eec, SPL version 35, published June 15, 2026 (effective 2026-05-29).
- Florian J, Salcedo P, Burkhart K, Shah A, Chekka LMS, Keshishi D, et al. (2025). Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med, 185(9):1070-1078.
- Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. (2020). Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology, 45(11):1799-1806.
- Smythe MA, Wu W, Garwood CL (2023). Anticoagulant drug-drug interactions with cannabinoids: A systematic review. Pharmacotherapy, 43(12):1327-1338.
- So GC, Lu JBL, Koyama S, Cheng YH, Gisch DL, McClara K, et al. (2025). A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus. Clin Pharmacol Ther, 117(3):716-723.
- Gidal BE, Vandrey R, Wallin C, Callan S, Sutton A, Saurer TB, Triemstra JL (2024). Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Front Pharmacol, 15:1335441. Sponsored by Jazz Pharmaceuticals, maker of Epidiolex.
- Johnson ED, Kilgore MW, Stafford M, Randolph M, Glover M, Babalonis S (2025). Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. Cannabis Cannabinoid Res, 10(6):710-718.
- Congressional Research Service (2026). Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (IF13136, updated September 28, 2026). CRS In Focus, congress.gov. Law: Public Law 119-37.
- Crippa JAS, Pacheco JC, Zuardi AW, Guimaraes FS, Campos AC, Osorio FL, et al. (2022). Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Cannabis Cannabinoid Res, 7(5):658-669.
- Morissette F, Mongeau-Perusse V, Rizkallah E, Thebault P, Lepage S, Brissette S, et al. (2021). Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. Neuropsychopharmacology, 46(12):2101-2111.
- Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, et al. (2017). Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial. Dig Dis Sci, 62(6):1615-1620.
- Jirasek P, Jusku A, Frankova J, Urbankova M, Diabelko D, Ruzicka F, et al. (2024). Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol. J Periodontal Res, 59(3):468-479.
- Botanix Pharmaceuticals (sponsor) (2022). A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris (NCT03573518). ClinicalTrials.gov (results first posted 2022-04-18).
- Botanix Pharmaceuticals (sponsor) (2022). A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis (NCT03824405). ClinicalTrials.gov (results first posted 2022-09-27).
- Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford), 45(1):50-2.
- Abidi AH, Kassan M, Derefinko K (2025). Oral Cannabidiol for Acute Post-Extraction Pain: A Randomized Pilot Study. Pharmaceuticals (Basel), 18(12).
- Luis SA, Klein AL, Cremer PC, Abbate A, Salik JR, Thomas GK, et al. (2026). Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial. J Am Heart Assoc, 15(14):e047605.
- Gisch DL, Koyama S, Etkins J, So GC, Fehrenbach DJ, Lu JBL, et al. (2026). Cannabidiol exerts antiinflammatory effects but maintains T effector memory cell differentiation in humans. JCI Insight, 11(1).
- Bryan AD, Skrzynski CJ, Yang J, Chrystal KA, Bidwell LC, Hutchison KE, Perreault L (2026). Inhaling high THC cannabis acutely increases inflammation but not insulin sensitivity: a quasi-randomized trial. Sci Rep, 16.
- Student V, Repa V, Vrbkova J, Vacek J (2026). Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 170(1):47-52. The product’s maker supported the study.
- Hobbs JM, Vazquez AR, Remijan ND, Trotter RE, McMillan TV, Freedman KE, et al. (2020). Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults. Phytother Res, 34(7):1696-1703.
- McNamara DM, Cooper LT, Friedrich MG, Arbel Y, Bhimaraj A, Bocchi E, et al. (2026). Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study. ESC Heart Fail, 13(1).
- Stauffer JW, Crow JA, Bishop MD, Cook RL, Borsa PA (2026). Efficacy and safety of cannabidiol (CBD) on reducing pain and functional impairment associated with exercise-induced muscle injury: a randomized placebo-controlled feasibility trial. J Cannabis Res, 8(1).
- Balachandran P, Elsohly M, Hill KP (2021). Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. J Gen Intern Med, 36(7):2074-2084.
- Wolinsky D, Zamarripa CA, Spindle TR, Klausner M, Cone EJ, Winecker RE, et al. (2026). The acute and chronic pharmacokinetics and pharmacodynamics of oral cannabidiol with and without low doses of delta-9-tetrahydrocannabinol. J Anal Toxicol, 50(1):bkaf075.
- Sideris A, Chan W, Liu J, Della Valle AG, Baaklini L, Rodriguez J, et al. (2026). Effects of cannabidiol (CBD) oral solution in patients undergoing bilateral total knee arthroplasty: A randomized, controlled, parallel, triple blind, pilot study. J Pain, 51:106477.
- Sahinovic A, Irwin C, Doohan PT, Kevin RC, Cox AJ, Lau NS, et al. (2022). Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. Sports Med Open, 8(1):27.
- Umpreecha C, Bhalang K, Charnvanich D, Luckanagul J (2023). Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial. BMC Complement Med Ther, 23(1):57.
- Mojoli A, Haider O, Fakih Y, Luz Goncalves MV, Zepeda Rojas B, Xaia G, et al. (2025). Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial – CANOA – cannabis for osteoarthritis. Front Pharmacol, 16:1657065.
- Fleege NMG, Miller EA, Kidwell KM, Zacharias ZR, Houtman J, Scheu K, et al. (2025). Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Breast Cancer. Cancer Med, 14(15):e71117.
- Bryan AD, Skrzynski CJ, Giordano G, Yang J, Stanger M, Bidwell LC, et al. (2025). Cannabis Use is Associated with Less Peripheral Inflammation but Similar Insulin Sensitivity as Nonuse in Healthy Adults. Am J Med, 138(9):1285-1295.
- Lisano JK, Skrzynski CJ, Giordano G, Bryan AD, Bidwell LC (2025). Inflammatory state moderates response to cannabis on negative affect and sleep quality in individuals with anxiety. Front Behav Neurosci, 19:1549311.
- Perez E, Fernandez JR, Fitzgerald C, Rouzard K, Tamura M, Savile C (2022). In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. Molecules, 27(2). The authors are employees of the companies that make the CBG and hold stock or stock options.
- de Abreu LM, Biancardi MR, Di Benedetto M, Sanches RM, Cardoso CL, Rubira CMF, et al. (2025). Therapeutic potential of cannabidiol in oral disorders: A systematic review of clinical evidence. J Am Dent Assoc, 156(10):838-850.e2.
- Komane B, Kaye T (2026). CBD-Containing Hemp Extracts and Isolated CBD for Acne: A Systematic Review of Anti-Inflammatory Mechanisms, Clinical Signals and Sustainability. Molecules, 31(12).
- Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O’Sullivan SE (2019). A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol, 85(9):1888-1900.
- Mboumba Bouassa RS, Needham J, Nohynek D, Samarani S, Bobeuf F, Del Balso L, et al. (2024). Feasibility of a Randomized, Interventional Pilot Clinical Study of Oral Cannabinoids in People with HIV on Antiretroviral Therapy: CTNPT 028. J Pers Med, 14(7). Tilray supplied the study capsules and gave no funding.
- Zintziovas N, Karakosta A, Voulgari P, Stefanakis G, Arnaoutoglou E, Tzimas P, Micha G (2026). Cannabinoids for pain management in rheumatoid arthritis: a scoping review of clinical evidence and mechanisms. Rheumatol Int, 46(10).
- Jugl S, Perez-Vilar S, Galati S, Sandhu SK, Chen HK, Chang SH, et al. (2026). Effectiveness of THC-containing cannabis for inflammatory bowel disease: a systematic review. J Cannabis Res, 8(1).
- Doeve BH, van de Meeberg MM, van Schaik FDM, Fidder HH (2021). A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease: What Can We Learn From Randomized and Nonrandomized Studies?. J Clin Gastroenterol, 55(9):798-809.
- Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, et al. (2019). The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflamm Bowel Dis, 25(3):427-435. Commissioned by the Crohn’s and Colitis Foundation.
- Kafil TS, Nguyen TM, MacDonald JK, Chande N (2018). Cannabis for the treatment of Crohn’s disease. Cochrane Database Syst Rev, 11(11):CD012853.
- Kafil TS, Nguyen TM, MacDonald JK, Chande N (2018). Cannabis for the treatment of ulcerative colitis. Cochrane Database Syst Rev, 11(11):CD012954.
- Wang S, Lin X, Liao F, Liang Y, Wang C, Gan L (2026). Efficacy of Exogenous Cannabinoids in Pre-Clinical Models of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Cannabis Cannabinoid Res, 11(4):297-313.
- Atalay S, Jarocka-Karpowicz I, Skrzydlewska E (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants (Basel), 9(1).
- Nichols JM, Kaplan BLF (2020). Immune Responses Regulated by Cannabidiol. Cannabis Cannabinoid Res, 5(1):12-31.
- Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol, 153(2):199-215. Writing supported by grants from the National Institute on Drug Abuse, the Biotechnology and Biological Sciences Research Council and GW Pharmaceuticals.
- O’Sullivan SE (2016). An update on PPAR activation by cannabinoids. Br J Pharmacol, 173(12):1899-910.



